Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.

Hitoshi Takahashi1, Takio Sugita, Hisashi Higuchi

  • 1Department of Neuropsychiatry, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan. hitoshit@psy.med.akita-u.ac.jp

Human Psychopharmacology
|October 31, 2002
PubMed
Summary

Adding fluvoxamine to risperidone did not improve residual symptoms in chronic schizophrenia patients. This open trial found no significant changes in Positive and Negative Syndrome Scale (PANSS) or extrapyramidal effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autophagy mediators (FOXO1, SESN3 and TSC2) in Lewy body disease and aging.

Neuroscience letters·2018
Same author

Histopathologic features of an autopsied patient with cerebral small vessel disease and a heterozygous HTRA1 mutation.

Neuropathology : official journal of the Japanese Society of Neuropathology·2018
Same author

Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin.

Japanese journal of infectious diseases·2018
Same author

Effects of the -141C insertion/deletion polymorphism in the dopamine D2 receptor gene on the dopamine system in the striatum in patients with schizophrenia.

Psychiatry research·2018
Same author

Establishment of the cross-clade antigen detection system for H5 subtype influenza viruses using peptide monoclonal antibodies specific for influenza virus H5 hemagglutinin.

Biochemical and biophysical research communications·2018
Same author

Expansions of intronic TTTCA and TTTTA repeats in benign adult familial myoclonic epilepsy.

Nature genetics·2018

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Chronic schizophrenia often presents residual positive and negative symptoms despite treatment.
  • Risperidone is a common antipsychotic, but treatment response can be incomplete.
  • Augmentation strategies are explored to enhance efficacy in treatment-resistant cases.

Purpose of the Study:

  • To evaluate the efficacy and safety of adding fluvoxamine to risperidone.
  • To assess the impact on residual positive and negative symptoms in chronic schizophrenia.
  • To determine if fluvoxamine augmentation improves outcomes in patients with incomplete risperidone response.

Main Methods:

  • An open-label trial involving 30 patients with chronic schizophrenia.
  • Fluvoxamine was added to existing risperidone treatment for 12 weeks.

Related Experiment Videos

  • Symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS) and Simpson-Angus (S-A) scale at multiple time points.

    • Main Results:

    • No significant improvements were observed in PANSS positive, negative, or general psychopathology scores.
    • No significant changes were noted in Simpson-Angus extrapyramidal effects scores.
    • Fluvoxamine augmentation did not demonstrate added benefit over risperidone monotherapy in this cohort.

    Conclusions:

    • Fluvoxamine appears ineffective as an augmentation agent for risperidone in treating residual symptoms of chronic schizophrenia.
    • Further investigation through controlled trials is warranted to confirm these findings.
    • The combination did not lead to increased extrapyramidal side effects during the study period.